Drug
Fruquintinib
Fruquintinib: highest development phase Phase 2, developed by Hutchmed, United Therapeutics. 7 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Hutchmed, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Fruquintinib NCT03684967 | Phase 2 | Lung Cancer |
| Fruquintinib NCT02976116 | Phase 2 | NSCLC |
| Fruquintinib NCT02590965 | Phase 2 | Non-small Cell Lung Cancer |
| Fruquintinib (HMPL-013) NCT03251378 | Phase 1 | Advanced Solid Tumors |
| Fruquintinib NCT05216367 | Phase 1 | Hepatic Impairment |
| fruquintinib NCT01955304 | Phase 1 | Food Effect of Fruquintinib in Health Subjects |
| Fruquintinib NCT04557397 | Phase 1 | Drug Drug Interaction |
Latest
No recent events.
Follow Fruquintinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.